Welcome to BioMarket Group!

Benchmarking Best Practice at Patent Expiry in Europe - Maximizing Return on Investment of Late-Stage Lifecycle Management

Additional Information

Published Date Dec 13, 2004
Special Offer

When you buy this report, you may pick 3 additional cancer reports for free from this list
(Value: More than 7,000 USD) Use the contact form for more details.

Pages 172
PDF Fact Sheet View Fact Sheet for the report Benchmarking Best Practice at Patent Expiry in Europe - Maximizing Return on Investment of Late-Stage Lifecycle Management in PDF format.
Published on Date No
Format No
Publisher Datamonitor
Product Line No
Full Title Benchmarking Best Practice at Patent Expiry in Europe - Maximizing Return on Investment of Late-Stage Lifecycle Management

Availability: In stock

$15,200.00

Quick Overview

Successfully managing the lifecycle of molecules within marketed portfolios is an essential capability for the pharma industry. With R&D productivity stalling, and profit margins increasingly eroded by cost containment initiatives, maximizing the return on investment of in-line brands, by extending the time on the market without generic competition, is a key objective for pharmaceutical companies.
Request free sample pages from Benchmarking Best Practice at Patent Expiry in Europe - Maximizing Return on Investment of Late-Stage Lifecycle Management

Introduction

Successfully managing the lifecycle of molecules within marketed portfolios is an essential capability for the pharma industry. With R&D productivity stalling, and profit margins increasingly eroded by cost containment initiatives, maximizing the return on investment of in-line brands, by extending the time on the market without generic competition, is a key objective for pharmaceutical companies.

Scope

  • Analysis of Datamonitor’s Patent Expiry Database of between 37 and 46 patent expiries in each of the UK, France, Germany, Italy and Spain
  • Primary research with 100 hospital and retail pharmacists across the five major European markets
  • Recommendations for market-specific best practice strategies at patent expiry, based on case studies and future focused environmental assessment
  • Analysis of the capabilities of 65 generics players operating in the UK, Germany, France, Spain and Italy

Highlights

The introduction of German reference price groups containing on- and off-patent brands has major implications for use of 2nd generation launches as a franchise protection strategy. If the follow-on product is not a significant improvement over the original, it risks having its reimbursement price linked to generic versions of the old molecule.

Despite the smaller number of generics companies launching generic injectables in Europe, analysis indicates injectables suffer no less generic erosion than oral products. Originator companies with injectable brands cannot expect to be shielded from full force of generic competition simply because fewer manufacturers have injectable capabilities.

Payers are the most influential stakeholders in most of the five major European markets, limiting the effectiveness of physician targeted brand protection strategies. France is the exception, where patient and physician brand loyalty has the potential to maintain sales of the branded product in the post-patent environment.

Reasons to Purchase

  • Identify the optimal late stage lifecycle management strategy for your brand
  • Identify the key stakeholders to target to secure success of your chosen brand protection strategy
  • Predict the impact of patent expiry on a brand, assisting with brand business planning or generic target identification
Request free sample pages from Benchmarking Best Practice at Patent Expiry in Europe - Maximizing Return on Investment of Late-Stage Lifecycle Management

Other selected research from the 'Europe' category:


European Biotech Industry Guide 2007, 5th Ed.
This exciting intelligence CD-ROM on European biotech industry has become better, stronger and more intelligent in its 5th Edition. Learn More


Website Benchmarking Service - European Physician and Consumer Targeted Websites
Due to the restrictions on direct-to-consumer advertising in Europe, pharmaceutical companies need to find an effective way to provide information to European consumers. The availability of physician-targeted websites is also more limited in Europe and the security of these sites is often much tighter than the sites provided to US physicians. Learn More

Other selected research from the 'Management' category:


Product Lifecycle Management, 2006
The global pharmaceutical market with sales of approximately $550 billion is about to enter a pivotal period in its history. The industry has been used to double digit growth rates but growth has now dropped to below 10% for the first time... Learn More


Benchmarking Best Practice at Patent Expiry in Europe - Maximizing Return on Investment of Late-Stage Lifecycle Management
Successfully managing the lifecycle of molecules within marketed portfolios is an essential capability for the pharma industry. With R&D productivity stalling, and profit margins increasingly eroded by cost containment initiatives, maximizing the return on investment of in-line brands, by extending the time on the market without generic competition, is a key objective for pharmaceutical companies. Learn More

Other selected research from the 'Pharmacoeconomics' category:


Indication Expansion: Opportunities for successful lifecycle management
Use the case studies in this report to identify best practice examples of indication expansion strategies and ensure that you can implement these into your current processes to maximize the lifecycle of your products. Learn More


Pricing and Reimbursement in the US: Innovation and robust pharmacoeconomic analysis are key
The US is the leading global drugs market in terms of sales and profit margin. However, drug companies are facing an unprecedented number of challenges in maintaining revenue growth: fewer drugs are being approved, a wide number of blockbusters are facing patent expiry, and payers are implementing stringent cost-containment policies in the face of sky-rocketing healthcare costs. Learn More